Emerging B-Cell Therapies in Systemic Lupus Erythematosus

被引：53

作者：

Bag-Ozbek, Ayse ^{[1
]}

Hui-Yuen, Joyce S. ^{[2
,3
,4
]}

机构：

[1] SUNY Stony Brook, Med Ctr, Renaissance Sch Med, Div Rheumatol, Stony Brook, NY 11794 USA

[2] Steven & Alexandra Cohen Children Med Ctr, Div Pediat Rheumatol, 1991 Marcus Ave,Suite M100, New Hyde Pk, NY 11040 USA

[3] Hofstra Northwell, Zucker Sch Med, Hempstead, NY USA

[4] Feinstein Inst Med Res, Ctr Autoimmune Musculoskeletal & Hematopoiet Dis, Manhasset, NY USA

来源：

THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2021年 / 17卷

关键词：

systemic lupus erythematosus; treatment; novel B-cell therapies; belimumab; rituximab; epratuzumab; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; LYMPHOCYTE STIMULATOR LEVELS; DEPLETES PLASMA-CELLS; HIGH DISEASE-ACTIVITY; DOUBLE-BLIND; PROTEASOME INHIBITORS; PHASE-III; RITUXIMAB; BELIMUMAB; SAFETY;

D O I：

10.2147/TCRM.S252592

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta (R)), a fully humanized monoclonal antibody inhibiting B-cell activation and proliferation, was the first medication in 50 years to be approved by the US Food and Drug Administration to treat adult SLE. This review discusses the current experience with B-cell-targeted therapies, including those targeting B-cell-surface antigens (rituximab, ocrelizumab, ofatumumab, obinutuzumab, obexelimab, epratuzumab, daratumumab), B-cell survival factors (belimumab, tabalumab, atacicept, blisibimod), or B-cell intracellular functions (ibrutinib, fenebrutinib, proteasome inhibitors), for the management of SLE. It focuses on ongoing clinical trials and real-world post-marketing use, where available, including their safety profiles, and concludes with our recommendations for B-cell-centric approaches to the management of SLE.

引用

页码：39 / 54

页数：16

共 89 条

[1] Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus [J].

Albert, D. ;

Dunham, J. ;

Khan, S. ;

Stansberry, J. ;

Kolasinski, S. ;

Tsai, D. ;

Pullman-Mooar, S. ;

Barnack, F. ;

Striebich, C. ;

Looney, R. J. ;

Prak, E. T. Luning ;

Kimberly, R. ;

Zhang, Y. ;

Eisenberg, R. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (12) :1724-1731

[2] Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors [J].

Alexander, Tobias ;

Cheng, Qingyu ;

Klotsche, Jens ;

Khodadadi, Laleh ;

Waka, Aderajew ;

Biesen, Robert ;

Hoyer, Bimba F. ;

Burmester, Gerd R. ;

Radbruch, Andreas ;

Hiepe, Falk .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2018, 48 (09) :1573-1579

[3] The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus [J].

Alexander, Tobias ;

Sarfert, Ramona ;

Klotsche, Jens ;

Kuehl, Anja A. ;

Rubbert-Roth, Andrea ;

Lorenz, Hannes-Martin ;

Rech, Juergen ;

Hoyer, Bimba F. ;

Cheng, Qingyu ;

Waka, Aderajew ;

Taddeo, Adriano ;

Wiesener, Michael ;

Schett, Georg ;

Burmester, Gerd-Ruediger ;

Radbruch, Andreas ;

Hiepe, Falk ;

Voll, Reinhard E. .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (07) :1474-1478

[4]

[Anonymous], 2014, BLOOD

[5] Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus [J].

Askanase, Anca D. ;

Wallace, Daniel J. ;

Weisman, Michael H. ;

Tseng, Chung-E ;

Bernstein, Lana ;

Belmont, H. Michael ;

Seidman, Ernest ;

Ishimori, Mariko ;

Izmirly, Peter M. ;

Buyon, Jill P. .

JOURNAL OF RHEUMATOLOGY, 2009, 36 (01) :89-95

[6]

Atisha F, 2020, ARTHRITIS RHEUMATOL, DOI [10.1002/art.41466, DOI 10.1002/ART.41466]

[7] Mortality in systemic lupus erythematosus [J].

Bernatsky, S. ;

Boivin, J. -F. ;

Joseph, L. ;

Manzi, S. ;

Ginzler, E. ;

Gladman, D. D. ;

Urowitz, M. ;

Fortin, P. R. ;

Petri, M. ;

Barr, S. ;

Gordon, C. ;

Bae, S. -C. ;

Isenberg, D. ;

Zoma, A. ;

Aranow, C. ;

Dooley, M. -A. ;

Nived, O. ;

Sturfelt, G. ;

Steinsson, K. ;

Alarcon, G. ;

Senecal, J. -L. ;

Zummer, M. ;

Hanly, J. ;

Ensworth, S. ;

Pope, J. ;

Edworthy, S. ;

Rahman, A. ;

Sibley, J. ;

El-Gabalawy, H. ;

McCarthy, T. ;

Pierre, Y. St. ;

Clarke, A. ;

Ramsey-Goldman, R. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2550-2557

[8] The Science Behind Biosimilars Entering a New Era of Biologic Therapy [J].

Bridges, S. Louis, Jr. ;

White, Douglas W. ;

Worthing, Angus B. ;

Gravallese, Ellen M. ;

O'Dell, James R. ;

Nola, Kamala ;

Kay, Jonathan ;

Cohen, Stanley B. .

ARTHRITIS & RHEUMATOLOGY, 2018, 70 (03) :334-344

[9] Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care [J].

Bruce, I. N. ;

Urowitz, M. ;

van Vollenhoven, R. ;

Aranow, C. ;

Fettiplace, J. ;

Oldham, M. ;

Wilson, B. ;

Molta, C. ;

Roth, D. ;

Gordon, D. .

LUPUS, 2016, 25 (07) :699-709

[10] Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial [J].

Brunner, Hermine, I ;

Abud-Mendoza, Carlos ;

Viola, Diego O. ;

Calvo Penades, Inmaculada ;

Levy, Deborah ;

Anton, Jordi ;

Calderon, Julia E. ;

Chasnyk, Vyacheslav G. ;

Ferrandiz, Manuel A. ;

Keltsev, Vladimir ;

Paz Gastanaga, Maria E. ;

Shishov, Michael ;

Boteanu, Alina Lucica ;

Henrickson, Michael ;

Bass, Damon ;

Clark, Kenneth ;

Hammer, Anne ;

Ji, Beulah N. ;

Nino, Antonio ;

Roth, David A. ;

Struemper, Herbert ;

Wang, Mei-Lun ;

Martini, Alberto ;

Lovell, Daniel ;

Ruperto, Nicolino .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) :1340-1348

← 1 2 3 4 5 6 7 8 9 →